## REMARKS

Claims 1-116 are pending. Claims 1-94 and 97-116 are subject to a restriction requirement. Claims 95 and 96 were withdrawn from consideration. Claim 95 has been amended.

Claim 95 was amended to correct the dependency. No new matter has been added.

## **Restriction Requirement**

Preliminarily, Applicants note that the Office Action indicated that claims 95 and 96 were withdrawn from consideration as being "uninterpretable". Applicants have amended claim 95 to correct its dependency. Applicants respectfully submit that claim 95 as amended and claim 96, which depends from claim 95, are interpretable and should be examined.

The Office Action has required Applicants to elect one of 37 allegedly patentably distinct inventions for examination. Applicants respectfully traverse the restriction requirement.

Applicants provisionally elect herein Group III, encompassing claims 36-38, drawn to antibodies. Applicants respectfully request that the Patent Office include within Group III claims 95 and 96, discussed above, which are also drawn to antibodies. Applicants elect for examination SEQ ID NO: 105.

Notwithstanding the foregoing, Applicants respectfully submit that the 37 groups of claims set forth by the Examiner are amenable to further grouping and that such further grouping would not impose a serious burden on the Examiner.

Applicants reserve the right to prosecute the claims encompassed by any of the non-elected groups in future continuing and/or divisional applications.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

DOCKET NO.:00069.US1

The examination of these claims and passage to allowance are respectfully

The examination of these claims and passage to allowance are respectfully requested. An early Notice of Allowance is therefore earnestly solicited. Applicants invite the Examiner to contact the undersigned at (215) 564-8338 to clarify any unresolved issues raised by this response.

Respectfully submitted,

wilym John Owen Attwell

Registration No. 45,449

Date: July 29, 2002 WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100

Attachments:

"Version with markings to show changes made"

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

## In the Claims:

Please amend claim 95 as follows:

95. **(Amended)** An isolated antibody which binds to an epitope on a polypeptide of claim [83] <u>90</u>.